Impact of free on-site vaccine and/or healthcare workers training on hepatitis B vaccination acceptability in high-risk subjects: a pre-post cluster randomized study  by Launay, O. et al.
Impact of free on-site vaccine and/or healthcare workers training on
hepatitis B vaccination acceptability in high-risk subjects: a pre-post
cluster randomized study
O. Launay1,2,3, Y. Le Strat4, W. Tosini5, L. Kara1,2,3, S. Quelet6, S. Levy7, J. Danan1,2,3, J. Reveillon1,2,3, J. Houdayer7, E. Bouvet5 and
D. Levy-Bruhl4; The ANRS-FORMVAC Study Group
1) Universite Paris Descartes, Sorbonne Paris Cite, 2) Inserm, CIC 1417, 3) Assistance Publique Ho^pitaux de Paris (AP-HP), Ho^pital Cochin, CIC Cochin Pasteur,
4) Institut de Veille Sanitaire, Saint-Maurice, 5) AP-HP, Groupe hospitalier Bichat-Claude Bernard, Centre de Depistage Anonyme et Gratuit (CDAG), 6) Direction
de l’action sociale, de l’enfance et de la sante and 7) Centre Regional d’Information et de Prevention du SIDA, Ile de France (CRIPS), Paris, France
Abstract
Despite recommendations for adults at high-risk of hepatitis B virus (HBV) infection, HBV vaccine uptake remains low in this
population. A pre-post randomized cluster study was conducted to evaluate the impact of on-site free HBV vaccine availability and/or
healthcare worker training on HBV vaccination acceptability in high-risk adults consulting in 12 free and anonymous HIV and hepatitis B/
C testing centres (FATC). The FATC were randomly allocated into three groups receiving a different intervention: training on HBV
epidemiology, risk factors and vaccination (Group A), free vaccination in the FATC (Group B), both interventions (Group C). The main
outcomes were the increase in HBV vaccination acceptability (receipt of at least one dose of vaccine) and vaccine coverage (receipt of
at least two doses of vaccine) after intervention. Respectively, 872 and 809 HBV-seronegative adults at high-risk for HBV infection were
included in the pre- and post-intervention assessments. HBV vaccination acceptability increased from 14.0% to 75.6% (p <0.001) in
Group B and from 17.1% to 85.8% (p <0.001) in Group C and HBV vaccine coverage increased from 9.4% to 48.8% (p <0.001) in
Group B and from 11.2% to 41.0% (p <0.001) in Group C. The association of training and free on-site vaccine availability was more
effective than free on-site vaccine availability alone to increase vaccination acceptability (ratio 1.14; from 1.02 to 1.26; p 0.017). No
effect of training alone was observed. These results support the policy of making HBV vaccine available in health structures attended by
high-risk individuals. Updating healthcare workers’ knowledge on HBV virus and its prevention brings an additional beneﬁt to
vaccination acceptability.
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Introduction
France is located in an area of low endemicity for hepatitis B
virus (HBV) infection (0.65% in the adult population), yet
hepatitis B remains a public health problem [1–3]. In line
with the WHO recommendations [4], the French HBV
vaccination policy in the general population includes the
routine vaccination of infants/children before they reach
15 years of age and adolescents/adults at high-risk of HBV
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infection [5]. HBV vaccine coverage is much lower in France
than reported in other European countries [6–8]. Several
studies have shown that a concern surrounding HBV vaccine
safety had a signiﬁcant impact both on the motivation of
practitioners to offer the vaccine and on the acceptability of
vaccination [9–11]. The French Ministry of Health has
therefore recently embarked on a policy of strengthening
the promotion of HBV vaccination for individuals at high-risk
for HBV infection [12].
The free and anonymous HIV and hepatitis B and C
testing centres (FATC) were set up by the French Health
authorities to facilitate access to anonymous, conﬁdential and
free HIV testing. Since 1999, their role was extended to
encompass the screening and prevention of hepatitis B and C
infections.
The aim of the present study was to evaluate the impact of
two public health interventions and their combination to
improve HBV vaccination acceptability and vaccine coverage in
subjects at risk for hepatitis B who are seen in FATC. As those
interventions were implemented at the level of the FATC, a
cluster design whereby the FATC were randomized to receive
a different intervention was used.
Materials and Methods
Participants
In the pre-intervention phase, FATC were randomly selected
from the national FATC activity database. FATC were
excluded if they did not screen HBV infection, saw fewer
than 1400 subjects per year or already proposed on-site HBV
vaccination (Fig. 1). FATC were asked not to change their
current practices regarding HBV screening and vaccination
during the pre-intervention assessment phase. At the end of
the pre-intervention phase, the FATC were randomly assigned
to each of the three intervention groups: training of healthcare
workers on HBV infection and its prevention (Group A), free
HBV vaccine administration in the FATC (Group B) or both
interventions (Group C).
In participating FATC, in both phases, all men and women
aged ≥18 years, with an HIV-negative test, with no immunity
against HBV (i.e. negative for HBV surface antigen (HBsAg),
anti-HBs and anti-HBc antibodies testing performed in the
FATC) and at high risk for HBV infection were consecutively
enrolled if they agreed to participate. Patients at high-risk for
hepatitis B infection were deﬁned according to the list of
individuals targeted by the hepatitis B vaccination recommen-
dations, mainly persons who have sex with multiple partners,
injecting drug users, travellers to countries of intermediate or
high HBV endemicity and close contacts of chronic carriers of
HBsAg [5]. Written informed consent was obtained from each
subject. The protocol was conducted in accordance with the
Declaration of Helsinki and French law for biomedical research
and was approved by the French Data Protection Agency
(CNIL) and by the ‘Ile-de-France 3’ Ethics Committee (Paris,
France).
Interventions
For healthcare worker training on HBV infection and its
prevention, one referral physician and one referral nurse
were designated from each FATC of groups A and C and
received a 1-day training outside the FATC in a specialized
healthcare centre committed to the prevention of HIV
infection and other sexually transmitted infections, including
hepatitis B and C, substance abuse and risk behaviours in
young people (Regional Centre for Information and Preven-
tion of Aids; CRIPS Ile-de-France, Paris, France). The training
team included a clinician, an epidemiologist and a health
education ofﬁcer, all specialized in hepatitis B infection and
control. The main topics addressed during the training
included general information about hepatitis B, risk factors
of HBV infection and at-risk populations, missions of FATC,
serological markers of hepatitis B and their interpretation,
HBV vaccination and the controversy over its safety. In
addition, a 2-h on-site training that focused on key messages
to motivate patients targeted by HBV vaccination was
performed on-site for all healthcare worker in each FATC
of Groups A and C by two clinicians specialized in hepatitis B
infection and control.
Objectives
We aimed to compare the effectiveness of improving the
acceptability of HBV vaccination by making the vaccine
available in the FATC, with that of increasing the capacity of
health staff to motivate the patients through a refresher
training. The third group, where both interventions were
implemented at the level of the FATC, aimed to test the
potential synergy between the two interventions.
Outcomes
The primary and secondary outcomes were the increase,
between the two phases, in the proportion of subjects that
received at least one dose (vaccination acceptability) or two
doses (vaccine coverage) of HBV vaccine.
Vaccination acceptability and vaccine coverage were
assessed, before and after intervention, following a similar
methodology. During the initial visit (visit V1), the physician
completed a case-report form for all subjects (willing or not to
participate in the study). The physician was free to prescribe
HBV vaccination and propose to the subjects that they
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participate in the study, including an agreement to provide
personal phone contact. If the subject declined to participate in
the study, the reasons were reported.
Three months after their inclusion (visit V2), the subjects
included in the study were called by phone by the study staff to
complete a questionnaire including the number of doses of
17 FATC included in the pre-
intervention assessment
Pre-intervention assessment: 12 FATC 
• 872 subjects at visit V1 before healthcare intervention 
• 163 subjects  [18.7%] lost to follow-up
• 709 at visit V2 at 3 months
Exclusion of 5 FATC with 
insufficient recruitment during
pre-intervention assessment 
Group B (4 FATC):
Intervention: On-site free 
HBV vaccine only
Group A (4 FATC):
Intervention: Training 
Group C (4 FATC):
Intervention: Training + on-site free 
HBV vaccine
300 FATC* in national FATC 
database
Exclusions of 228 FATC with no 
HBV screening, or insufficient 
activity (< 1400 patients/year)
Exclusion of 38 FATC with on-site 
HBV vaccination facilities 
17 eligible FATC refuse to 
participate
250 subjects at VI 321 subjects at V1 238 subjects at V1 
4FATC included in analysis 
182 subjects at V2  
Lost to follow up: n = 68 (27.2%) 
4FATC included in analysis
254 subjects at V2 
Lost to follow up: n = 67 (20.9%)
4FATC included in analysis
183 subjects at V2 
Lost to follow up: n = 55 (23.1%)
* FATC: Free and Anonymous HIV and hepatitis B and C Testing Centers
RANDOMISATION 
FIG. 1. Flow chart for participation of FATC and patients as well as randomization process. *FATC, Free and Anonymous HIV and hepatitis B and
C Testing Centres.
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HBV vaccines administered, the main reason for vaccination or
no vaccination and the date and place of vaccination.
Sample size
The sample size was estimated to allow the observation of a
15% difference in acceptability of HBV vaccination before and
after intervention in each group of FATC and between the
three groups after intervention. For a design effect estimated
at 1.2 and a loss of follow up estimated at 35%, 350
individuals per group were needed after intervention (with a
risk at 5%, and b risk at 10%) in the worst hypothesis for
HBV vaccination acceptability (42%) [13]. An interim analysis
conducted during the pre-intervention phase yielded an HBV
vaccination acceptability rate around 10% and a loss of
follow-up rate of <25%. A new calculation of the sample size
with the same a and b risks based on those ﬁgures yielded a
minimum sample size of 168 per group. Based on four FATC
in each of the three groups after intervention, the minimum
number of inclusions per FATC was set at 50. Subjects
already included above that ﬁgure in FATC with high
recruitment capacity were kept in the analysis. To account
for a possible drop-out of FATC between the ﬁrst and the
second phase, linked for instance to difﬁculties in recruiting
enough participants, it was decided to include 18 FATC in the
ﬁrst phase so as to have at least 12 FATC participating in the
second phase.
Sequence generation
As a result of the small number of clusters, a stratiﬁcation on
the annual level of HBV screening activity (low, moderate, high
activity) was used in the initial selection of FATC, to avoid an
unbalanced selection of FATC related to some of their
characteristics, such as their size. Those levels were deﬁned by
the 33rd and 66th centiles of number of subjects tested for
HBV immunity (corresponding to 2200 and 4000 subjects per
year, respectively). Therefore, six FATC were to be randomly
selected in each stratum.
The FATC that participated in the study in the pre-inter-
vention phase were randomly allocated to one of the three
intervention groups at the end of this phase. Randomization
was performed by one of the researchers (DLB) on an EXCEL
ﬁle where FATC were identiﬁed through a number not
allowing the identiﬁcation of the FATC.
Statistical analysis
In each of the three groups deﬁned by the intervention
implemented, HBV vaccination acceptability and coverage
were compared, before and after intervention. HBV vaccina-
tion acceptability and coverage were also compared between
groups within each phase.
The data were analysed using multivariate Poisson regression
models with robust variance taking into account the study design
[14,15]. The choice of this type of regression was based on our
objective to assess HBV vaccination acceptability/coverage
ratios rather than approximate them (e.g. odds ratio from
logistic regressions). The multivariate Poisson regressions to
explain HBV vaccination acceptability/coverage were adjusted
on the following potentially associated variables: delivery of a
prescription, sex, age, endemic rate of HBV in the country of
origin, close contacts with an HBV-infected individual, multiple
sexual partners, sexual partner with HBV infection, travelling/
living in country with moderate/high HBV prevalence, occupa-
tional risk. Agewas introduced as a continuous variablemodeled
with a fractional polynomial [16]. Two additional statistical
models were performed, including all the variables listed above:
one explored factors associated with HBV vaccination accept-
ability before intervention in the three groups considered
together; the other one explored the factors associated with
HBV vaccination acceptability and coverage after intervention in
group C. This latter analysis was aimed at identifying potential
residual risk factors associated with declining the proposal of
HBV vaccination despite the vaccine being available and free and
the staff having been recently re-trained.
Results
Selection of centres and subjects’ characteristics
Within all eligible FATC, 17 agreed to participate (six in a
stratum with low activity for HBV screening, six with moderate
activity and ﬁve with high activity; Fig. 1). Five FATC were
excluded at the end of the pre-intervention assessment due to
insufﬁcient recruitment (<30 subjects). In the 12 active FATC
(four FATC in each intervention group), 872 subjects were
included in the pre-intervention assessment (September 2009–
March 2010); 809 subjects were included in the post-interven-
tion assessment (September 2010–March 2011). One hundred
and three subjects (10.6%) declined to participate in the
pre-intervention assessment and 87 (9.7%) in the post-inter-
vention assessment. The distribution of patients before and
after intervention in the three groups, and patients lost to
follow up are reported in Fig. 1. The baseline characteristics of
the participants are described in Table 1. The characteristics of
patients who participated and of those who declined to
participate did not differ (see Supporting information; Table
S1). The subjects enrolled before and after intervention were
comparable except for homo/bisexual practices (p 0.009).
According to the multivariate regression model, no factor
was signiﬁcantly associated with loss to follow up after
3 months, both before and after intervention.
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HBV vaccination acceptability and vaccine coverage
Before intervention, HBV vaccination acceptability (at least
one dose of vaccine) did not differ between the three groups
determined by the randomization of FATC (14.9%, 14.0% and
17.1% in groups A, B and C, respectively; p 0.8). Adjusted on
age (p 0.09), the factors associated with HBV vaccination
acceptability before intervention when combining the three
groups were: delivery of an HBV vaccine prescription
(p <0.001), the level of endemicity of HBV in the country of
origin (p 0.04), having an HBV-infected sexual partner
(p 0.002) and having multiple sexual partners (p 0.01).
Acceptability of HBV vaccination increased signiﬁcantly after
intervention in Groups B and C (Fig. 2a). No signiﬁcant change
was observed in Group A. The association of training and HBV
vaccine availability (Group C) had a signiﬁcantly higher impact
on acceptability than vaccine availability alone (Group B; ratio,
1.14 (95% CI 1.02–1.26), p 0.017).
No factor was found to be signiﬁcantly associated with HBV
vaccination acceptability after intervention in Group C.
The HBV vaccine coverage (at least two doses of vaccine)
increased signiﬁcantly after intervention in Groups B and C
(Fig. 2b). No signiﬁcant change was observed in Group A. The
impact of the association of training and vaccine availability
(Group C) on vaccine coverage was not signiﬁcantly different
from that of vaccine availability alone (Group B).
Discussion
In this study, HBV vaccine availability induced a dramatic
increase in vaccination acceptability and, to a lesser extent, in
vaccine coverage. Training of healthcare workers alone had
no signiﬁcant impact on HBV vaccination acceptability or
coverage. One explanation for this disappointing result for
training could be that the prevention of HBV infection is
already included in FATC missions. Therefore, training
relying on the capacity and willingness of the regular FATC
staff to educate and motivate their patients does not appear
as a promising intervention to increase HBV vaccine
coverage.
Interestingly, healthcare worker training associated with
availability of free HBV vaccines did better than free vaccines
alone in terms of vaccination acceptability, but the difference
disappeared when considering the vaccine coverage. This
ﬁnding could reﬂect a transient synergy of training and free
vaccine availability that does not last beyond the immediate
incentive effect related to the interaction with trained staff
during the consultation.
Our results are comparable with the overall HBV vaccine
acceptance of 69% (55% for the second dose) reported in a
study conducted in a Californian sexually transmitted disease
clinic, where the HBV vaccine was administered without
additional charge [17]. Similarly, in a Dutch HBV vaccination
programme, where some Municipal Health Services offered
the HBV vaccine free to high-risk groups, the coverage in








Women 283 (40.3) 391 (64.1)
HBV prevalence in country of origin
<2% (low) 580 (84.7) 511 (85.9)
2–7% (moderate) 45 (6.6) 37 (6.2)
>7% (high) 60 (8.8) 47 (7.9)
Missing 24 24
Risk factorsa
Multiple sexual partners 574 (81.3) 508 (83.1)
Homosexual or bisexual 92 (13.1) 111 (18.3)
Sexual partner with HBV infection 8 (1.2) 6 (1.0)
Drug user 49 (7.0) 38 (6.4)
Travelling/living in country with
moderate/high prevalence
214 (30.5) 178 (29.7)
Professional risk 62 (8.9) 37 (6.3)
Close contacts infected by HBV 19 (2.7) 8 (1.3)
No social insurance 16 (2.3) 5 (0.8)
Results given as n (%). HBV, hepatitis B virus.
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FIG. 2. Evolution of HBV vaccination acceptability (a) and vaccine
coverage (b) according to the type of intervention (Group A: training
on hepatitis B virus infection and its prevention; Group B: free hepatitis
B virus vaccine administration in the centre; Group C: both
interventions), using a multivariate Poisson regression model.
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those who reported their status was 59% for the full
vaccination series [18]. Of interest, the HBV vaccine
coverage increased over time, suggesting the importance of
sustained efforts over many years in these high-risk popu-
lations. On-site provision of free vaccine has been shown to
increase healthcare workers’ inﬂuenza vaccination coverage
[19].
Our cluster randomized control trial design including a
before and after intervention assessment has allowed us to
minimize bias. The short duration of the study together with
the absence of increase in the vaccination coverage in the
group without free on-site HBV vaccine availability makes the
conclusion of the impact of this latter strategy on vaccine
coverage quite robust. The relatively low percentage of
refusal to participate in both phases, (around 10%) and of
loss to follow up at the 3-month visit (<25%) is another
strength of the study. One of its main limitations is that the
vaccination status was not validated through ofﬁcial records.
However, there is no reason to think that the potential bias
so induced would differ between groups or between phases
and it therefore does not affect our conclusions. Another
limitation is that only the ﬁrst two injections were
monitored. However, this was chosen to limit the delay
between the initial and the ﬁnal visit, and hence to reduce
the risk of loss to follow up of participants. Moreover,
recent data in adolescents suggested that two doses of
vaccine are sufﬁcient for protection [20].
In conclusion, the availability of free on-site HBV vaccine
was highly effective in increasing HBV vaccination acceptability
in high-risk adults. Further studies are necessary to identify the
barriers that still prevent a substantial number of high-risk
patients from achieving a complete HBV immunization
schedule when an immediate opportunity for vaccination is
offered by well-trained staff.
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